Analysts expect Natus Medical Incorporated (NASDAQ:BABY) to post sales of $145.85 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Natus Medical’s earnings, with the lowest sales estimate coming in at $145.50 million and the highest estimate coming in at $146.20 million. Natus Medical posted sales of $107.70 million during the same quarter last year, which suggests a positive year over year growth rate of 35.4%. The business is expected to report its next earnings report on Wednesday, February 7th.
According to Zacks, analysts expect that Natus Medical will report full year sales of $145.85 million for the current year, with estimates ranging from $515.10 million to $515.70 million. For the next fiscal year, analysts forecast that the business will report sales of $554.10 million per share, with estimates ranging from $552.40 million to $555.80 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Natus Medical.
Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.02. The business had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The business’s revenue for the quarter was up 34.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.39 EPS.
A number of research firms have recently weighed in on BABY. Zacks Investment Research raised Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price objective on the stock in a research report on Tuesday, October 24th. BidaskClub downgraded shares of Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $46.50.
Natus Medical (BABY) traded up $0.20 on Tuesday, reaching $38.20. The company had a trading volume of 747,690 shares, compared to its average volume of 393,447. Natus Medical has a 12-month low of $31.65 and a 12-month high of $43.85. The firm has a market capitalization of $1,180.00, a PE ratio of 26.35 and a beta of 0.89. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36.
In related news, Director William M. Moore sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $41.01, for a total transaction of $205,050.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert A. Gunst sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the sale, the director now owns 50,850 shares in the company, valued at approximately $1,788,394.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,042 shares of company stock valued at $902,266. 5.50% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in BABY. Alps Advisors Inc. boosted its holdings in shares of Natus Medical by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 12,906 shares of the medical equipment provider’s stock valued at $481,000 after buying an additional 33 shares during the period. Pinebridge Investments L.P. raised its holdings in shares of Natus Medical by 1.7% in the 2nd quarter. Pinebridge Investments L.P. now owns 4,359 shares of the medical equipment provider’s stock worth $163,000 after purchasing an additional 71 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Natus Medical by 0.7% during the second quarter. Louisiana State Employees Retirement System now owns 13,500 shares of the medical equipment provider’s stock valued at $504,000 after acquiring an additional 100 shares during the period. Arizona State Retirement System raised its holdings in shares of Natus Medical by 1.2% during the second quarter. Arizona State Retirement System now owns 17,306 shares of the medical equipment provider’s stock valued at $646,000 after acquiring an additional 200 shares during the period. Finally, Municipal Employees Retirement System of Michigan raised its holdings in shares of Natus Medical by 3.2% during the second quarter. Municipal Employees Retirement System of Michigan now owns 7,760 shares of the medical equipment provider’s stock valued at $289,000 after acquiring an additional 240 shares during the period. Institutional investors own 99.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “$145.85 Million in Sales Expected for Natus Medical Incorporated (BABY) This Quarter” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/11/17/145-85-million-in-sales-expected-for-natus-medical-incorporated-baby-this-quarter-2.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.